Axsome Therapeutics(AXSM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [6][12] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% year-over-year, and total sales for Auvelity reached $507.1 million, representing a 74% year-over-year increase [12][13] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [17] - Cash and cash equivalents at year-end were $323 million, compared to $315 million at the end of 2024 [18] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth in prescriptions [5][20] - Sunosi posted Q4 net product revenue of $36.7 million, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [13][25] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [14] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [20] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [21] - Symbravo's payer coverage is approximately 52% at the start of the year, with ongoing negotiations expected to expand this coverage [24] Company Strategy and Development Direction - The company is focused on scaling growth across its commercial organization and expanding adoption of CNS medicines [25] - A significant expansion of the Auvelity sales force to approximately 600 representatives is planned to support growth in MDD and potential Alzheimer's disease agitation [22][64] - The company is advancing a broad CNS pipeline, including five novel product candidates across nine high-impact indications [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential impact of Auvelity in addressing Alzheimer's disease agitation, with launch readiness activities underway [7][74] - The company anticipates continued momentum in its commercial business and expects to achieve cash flow positivity based on its current operating plan [18] - Management highlighted the importance of ongoing negotiations with payers to ensure access for both MDD and ADA indications [56] Other Important Information - The company has made significant progress in its CNS pipeline, including planned trials for AXS-05 in smoking cessation and AXS-12 in narcolepsy [8][9] - The company acquired AZD7325, a novel oral GABA A receptor modulator, to evaluate for the treatment of epilepsy [10] Q&A Session Summary Question: Implications of the new FDA publication on trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA [29][30] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the focus is currently on preparing for phase II readiness [35][36] Question: Coverage evolution for Auvelity post-ADA label approval - Existing coverage should generally apply to the new indication, but additional efforts are being made for Medicare coverage [40][41] Question: Drivers of Sunosi's growth - Growth is driven by both OSA and narcolepsy markets, with positive trends in new patient starts and prescriber behavior [48] Question: Progress of the DTC campaign for Auvelity - The national TV campaign has generated an inflection in new patient starts, with growth seen in primary care and psychiatry [52][53] Question: Expected reimbursement and market access for Auvelity - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives [56] Question: Coverage evolution for Symbravo - Secured contracts with large GPOs will facilitate negotiations with payers, with optimism about increasing coverage [68][70] Question: Launch readiness for Alzheimer's disease agitation - The company will be ready to launch within a quarter post-approval, with plans to share metrics on script percentages from the ADA space [74]